Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Metadata
Title
Phase 1 trial of Anvirzel™ in patients with refractory solid tumors
Authors
Tarek Mekhail
Hanspreet Kaur
Ram Ganapathi
G. Thomas Budd
Paul Elson
Ronald M. Bukowski
Publication date
01-09-2006
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 5/2006
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-006-7772-x

Other articles of this Issue 5/2006

Investigational New Drugs 5/2006 Go to the issue

Phase I Studies

Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx®) in combination with topotecan in patients with advanced malignancies

Preclinical Studies

The effect of single agent oral fusaric acid (FA) on the growth of subcuta neously xenografted SCC-1 cells in a nude mouse model

Preclinical Studies

Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer

Phase I Studies

A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies

Phase II Studies

Phase II study of vinflunine in patients with metastatic renal cell carcinoma

Case Report

Abraxane® induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits